Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People's Republic of China.
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People's Republic of China.
Hum Pathol. 2019 Feb;84:291-298. doi: 10.1016/j.humpath.2018.09.014. Epub 2018 Oct 5.
There is limited evidence regarding the relationship between programmed cell death ligand 1 (PD-L1) expression on tumor cells (TCs) and prognosis of esophageal squamous cell carcinoma (ESCC). This retrospective study aimed to investigate the clinical significance of PD-L1 expression in ESCC. To assess PD-L1 expression, we conducted immunohistochemistry studies using a tissue microarray encompassing 233 ESCC cases, stages I, II, and III, with detailed clinical data. PD-L1 expression on TCs was observed in 55.4% (129/233) of ESCC cases and was not associated with clinicopathological factors. ESCC patients with PD-L1-positive tumors showed significantly better overall survival and disease-free survival than did those with PD-L1-negative tumors (P = .023 and P = .026, respectively). When patients were stratified into those with stage I-II (127; 54.5%) and stage III (106; 45.5%) disease and those without (134; 57.5%) and with (99; 42.5%) lymph node metastasis, the prognostic effect was inconsistent. The overall survival and disease-free survival of patients with positive PD-L1 expression were significantly better in patients with stage I-II disease (P = .021 and P = .015, respectively) and without lymph node metastasis (P = .009 and P = .07, respectively) than their counterparts. Our results showed that PD-L1 expression on TCs was an independent predictor of prognosis of ESCC patients. However, the effect varied in patients with different stages and lymph node status. Positive PD-L1 expression was a favorable predictor in ESCC patients with stage I-II disease or without lymph node metastasis but not in patients with stage III disease or lymph node metastasis.
肿瘤细胞 (TCs) 程序性死亡配体 1 (PD-L1) 表达与食管鳞状细胞癌 (ESCC) 预后的关系证据有限。本回顾性研究旨在探讨 PD-L1 在 ESCC 中的临床意义。为了评估 PD-L1 表达，我们使用包含 233 例 ESCC 病例的组织微阵列进行了免疫组织化学研究，这些病例分期为 I、II 和 III，具有详细的临床数据。在 233 例 ESCC 病例中，有 55.4%（129/233）观察到 TCs 上的 PD-L1 表达，且与临床病理因素无关。PD-L1 阳性肿瘤的 ESCC 患者的总生存期和无病生存期明显优于 PD-L1 阴性肿瘤的患者（P=0.023 和 P=0.026）。当患者分为 I-II 期（127 例；54.5%）和 III 期（106 例；45.5%）以及无（134 例；57.5%）和有（99 例；42.5%）淋巴结转移的患者时，预后效果不一致。在 I-II 期疾病患者（P=0.021 和 P=0.015）和无淋巴结转移患者（P=0.009 和 P=0.07）中，PD-L1 阳性表达患者的总生存期和无病生存期明显优于相应患者。我们的结果表明，TCs 上的 PD-L1 表达是 ESCC 患者预后的独立预测因子。然而，在不同分期和淋巴结状态的患者中，其效果存在差异。在 I-II 期疾病或无淋巴结转移的 ESCC 患者中，PD-L1 阳性表达是一个有利的预测因素，但在 III 期疾病或淋巴结转移的患者中并非如此。
